Osteoporosis care in the United States after declines in reimbursements for DXA

Journal of Clinical Densitometry

Volumn 13, Issue 4, 2010, Pages 352-360

  Hayes, Burton L ^a   Curtis, Jeffrey R ^b   Laster, Andrew ^c   Saag, Kenneth ^c   Tanner, S Bobo ^d   Liu, Caiqin ^a   Womack, Catherine ^a   Johnson, Karen C ^a   Khaliq, Fazila ^a   Carbone, Laura D ^a,e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b The University of Alabama at Birmingham   (United States)

^c Arthritis and Osteoporosis Consultants of the Carolinas   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e Affairs Medical Center   (United States)

Author keywords

DXA; Medicare cuts; United States

Indexed keywords

AGED; ARTICLE; BONE DENSITOMETRY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDUCATION; HEALTH SURVEY; HUMAN; MEDICAL FEE; MEDICAL PRACTICE; MEDICARE; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; CHI-SQUARE DISTRIBUTION; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES;

EID: 77958511695     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2010.08.001     Document Type: Article

References (13)

1. Curtis J.R., Laster A., Becker D.J., et al. The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporos Int 2008, 20(9):1553-1561. PMC2728788.
2. Laster A., Federal Register, CMS 1321-FC Available at:, Accessed: July 15, 2010. http://www.iscd.org/visitors/positions/CMS-1321-FCRevisedDXAandVFApayments.pps.
3. Federal Register, Department of Health and Human Services, Editor. 2009. p. 61737-62206.
4. The Lewin Group Assessing the Cost of Performing DXA Services in the Office Based Setting. Final Report Available at:, Accessed: October 31, 2007. http://www.aace.com/advocacy/leg/pdfs/DXAExecutiveSummary.pdf.
5. Smith M.D., Ross W., Ahern M.J. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip and wrist fractures. J Rheumatol 2001, 28(11):2504-2508.
6. Federal Register. 2002. p. 11667.
7. Nelson H.D. Menopause. Lancet 2008, 371(9614):760-770.
8. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(23):2727-2741.
9. Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol 2009, 115(1):132-134.
10. Mazmanian P.E., Davis D.A. Continuing medical education and the physician as a learner: guide to the evidence. JAMA 2002, 288(9):1057-1060.
11. Laster A. A crisis in health care: access to osteoporosis diagnosis and treatment is endangered (overview). ISCD Annual Meeting, Tampa, FL, 2007.
12. American College of Radiology Moran Study: Advanced Imaging Growth Lower than Other Physician Services 2004-2010 Available at:, [reprinted with permission]. Accessed: July 15, 2010. http://www.acr.org/Hidden/Economics/FeaturedCategories/WhatsNew/MoranStudyLowGrowth.aspx.
13. Zhang Y., Donohue J.M., Lave J.R., et al. The effect of Medicare Part D on drug and medical spending. N Engl J Med 2009, 361(1):52-61.